Endocrine Abstracts

Introduction: Alemtuzumab, a humanized monoclonal antibody against CD52, is effective in the treatment of early relapsing-remitting multiple sclerosis (MS). Thyroid side-effects such as Graves’ disease have been already described. We describe one case of unusual subacute thyroiditis after alemtuzumab treatment.Clinical case: A 38 year-old-female was treated by alemtuzumab for 2 years. She was referred for hyperthyroidism with 10 kg weight loss, diar...